Raveron versus placebo in the conservative treatment of benign prostatic hyperplasia (BPH)

Thirty patients with BPH were randomized into two groups to receive Raveron and placebo for 6 weeks. The subjective and objective signs associated with BPH were evaluated before and after treatment. There was no significant difference between the effects of Raveron and placebo.

Saved in:
Bibliographic Details
Published in:International urology and nephrology 1990-07, Vol.22 (4), p.345-348
Main Authors: Bircan, K, Ozen, H A, Ergen, A, Başar, I, Ozgür, S, Ilker, Y, Karaağaoğlu, E, Remzi, D
Format: Article
Language:English
Subjects:
Double-Blind Method
Humans
Male
Middle Aged
Placebos
Prospective Studies
Prostatic Hyperplasia - drug therapy
Tissue Extracts - therapeutic use
Urodynamics - drug effects
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thirty patients with BPH were randomized into two groups to receive Raveron and placebo for 6 weeks. The subjective and objective signs associated with BPH were evaluated before and after treatment. There was no significant difference between the effects of Raveron and placebo.
ISSN:0301-1623
1573-2584
DOI:10.1007/BF02549794